179 related articles for article (PubMed ID: 19578778)
1. Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition.
Engel JB; Schönhals T; Weidler C; Häusler S; Krockenberger M; Rieger L; Dietl J; Wischhusen J; Honig A
Oncol Rep; 2009 Aug; 22(2):361-7. PubMed ID: 19578778
[TBL] [Abstract][Full Text] [Related]
2. Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells.
Engel JB; Hahne JC; Häusler SF; Meyer S; Segerer SE; Diessner J; Dietl J; Honig A
Anticancer Res; 2012 May; 32(5):2063-8. PubMed ID: 22593489
[TBL] [Abstract][Full Text] [Related]
3. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
Engel JB; Honig A; Schönhals T; Weidler C; Häusler S; Krockenberger M; Grunewald TG; Dombrowski Y; Rieger L; Dietl J; Wischhusen J
Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):64-9. PubMed ID: 18687514
[TBL] [Abstract][Full Text] [Related]
4. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2008 May; 21(5):637-43. PubMed ID: 18425357
[TBL] [Abstract][Full Text] [Related]
5. PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer.
Honig A; Hahne JC; Meyer S; Kranke P; Häusler S; Diessner J; Dietl J; Engel JB
Anticancer Res; 2012 May; 32(5):2035-41. PubMed ID: 22593485
[TBL] [Abstract][Full Text] [Related]
6. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2006 Feb; 17(2):323-9. PubMed ID: 16391833
[TBL] [Abstract][Full Text] [Related]
7. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Ueda T; Takai N; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2007 Feb; 19(2):301-8. PubMed ID: 17203205
[TBL] [Abstract][Full Text] [Related]
8. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma.
Nici L; Monfils B; Calabresi P
Clin Cancer Res; 2004 Nov; 10(22):7655-61. PubMed ID: 15569998
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.
Borri P; Coronnello M; Noci I; Pesciullesi A; Peri A; Caligiani R; Maggi M; Torricelli F; Scarselli G; Chieffi O; Mazzei T; Mini E
Gynecol Oncol; 1998 Dec; 71(3):396-403. PubMed ID: 9887238
[TBL] [Abstract][Full Text] [Related]
10. Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells.
Takai N; Ueda T; Nasu K; Narahara H
Gynecol Oncol; 2008 Nov; 111(2):336-43. PubMed ID: 18790523
[TBL] [Abstract][Full Text] [Related]
11. Phenoxazine derivatives induce caspase-independent cell death in human glioblastoma cell lines, A-172 and U-251 MG.
Shirato K; Imaizumi K; Abe A; Tomoda A
Oncol Rep; 2007 Jan; 17(1):201-8. PubMed ID: 17143499
[TBL] [Abstract][Full Text] [Related]
12. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
[TBL] [Abstract][Full Text] [Related]
13. Beta-hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Gynecol Oncol; 2008 Apr; 109(1):107-14. PubMed ID: 18234298
[TBL] [Abstract][Full Text] [Related]
14. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
15. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent.
Calabresi P; Goulette FA; Darnowski JW
Cancer Res; 2001 Sep; 61(18):6816-21. PubMed ID: 11559556
[TBL] [Abstract][Full Text] [Related]
16. Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide.
Iguchi T; Yachide-Noguchi T; Hashimoto Y; Nakazato S; Sagawa M; Ikeda Y; Kizaki M
Int J Mol Med; 2008 Feb; 21(2):163-8. PubMed ID: 18204782
[TBL] [Abstract][Full Text] [Related]
17. Novel target genes responsive to the anti-growth activity of triptolide in endometrial and ovarian cancer cells.
Li H; Takai N; Yuge A; Furukawa Y; Tsuno A; Tsukamoto Y; Kong S; Moriyama M; Narahara H
Cancer Lett; 2010 Nov; 297(2):198-206. PubMed ID: 20547442
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activity and cytostatic mechanism of novel 2-arylbenzo[b]furans.
Yang H; Pang JY; Cai YC; Xu ZL; Xian LJ
J Pharm Pharmacol; 2006 Sep; 58(9):1281-7. PubMed ID: 16945188
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines.
Navo MA; Smith JA; Gaikwad A; Burke T; Brown J; Ramondetta LM
Cancer Chemother Pharmacol; 2008 Aug; 62(3):483-9. PubMed ID: 18004570
[TBL] [Abstract][Full Text] [Related]
20. Role of cell cycle events and apoptosis in mediating the anti-cancer activity of a silver(I) complex of 4-hydroxy-3-nitro-coumarin-bis(phenanthroline) in human malignant cancer cells.
Thati B; Noble A; Creaven BS; Walsh M; McCann M; Devereux M; Kavanagh K; Egan DA
Eur J Pharmacol; 2009 Jan; 602(2-3):203-14. PubMed ID: 19041861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
